Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 13/20 | 0.51 |
| ▸ | TNK2 | Q07912 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28724598 | 0.95 | IGF1R (0.49) | IGF1RTNK2SMN1; SMN2CYP2C19 | |
| SCHEMBL21050808 | 0.95 | IGF1R (0.49) | IGF1RTNK2SMN1; SMN2CYP2C19 | |
| SCHEMBL21050896 | 0.91 | IGF1R (0.50) | IGF1RTNK2 | |
| SCHEMBL15929297 | 0.90 | IGF1R (0.51) | IGF1RTNK2 | |
| SCHEMBL2322562 | 0.89 | SMN1; SMN2 (0.47) | TNK2SMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL593894 | 0.89 | IGF1R (0.51) | IGF1RTNK2SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL27030777 | 0.87 | SMN1; SMN2 (0.46) | IGF1RTNK2SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL30449939 | 0.86 | IGF1R (0.49) | IGF1RTNK2 | |
| SCHEMBL14630466 | 0.85 | GRIN2B (0.49) | IGF1RTNK2GRIN2B | |
| SCHEMBL14630518 | 0.85 | BTK (0.48) | IGF1RTNK2SMN1; SMN2CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734529-B1 | BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9718828-B2 | BTK Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170008899-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20140221333-A1 | BTK INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-08-07 | — | — | US | disclosed |
| EP-2548877-A1 | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors | MSD Oss B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008899-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | IGF1R 970/4885TNK2 203/4885SMN1; SMN2 3846/4885 |
| US-20140221333-A1 | BTK INHIBITORS | BTK, SYK, ABL1 | IGF1R 1041/4885TNK2 188/4885SMN1; SMN2 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.